301 related articles for article (PubMed ID: 34359767)
1. The Role of Natural Killer Cells in Soft Tissue Sarcoma: Prospects for Immunotherapy.
Fortes-Andrade T; Almeida JS; Sousa LM; Santos-Rosa M; Freitas-Tavares P; Casanova JM; Rodrigues-Santos P
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359767
[TBL] [Abstract][Full Text] [Related]
2. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome Analysis of Tumor-Infiltrating Lymphocytes Identifies NK Cell Gene Signatures Associated With Lymphocyte Infiltration and Survival in Soft Tissue Sarcomas.
Judge SJ; Bloomstein JD; Sholevar CJ; Darrow MA; Stoffel KM; Vick LV; Dunai C; Cruz SM; Razmara AM; Monjazeb AM; Rebhun RB; Murphy WJ; Canter RJ
Front Immunol; 2022; 13():893177. PubMed ID: 35874727
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive genomic analysis of primary bone sarcomas reveals different genetic patterns compared with soft tissue sarcomas.
Zhang Q; Yang Y; You X; Ju Y; Zhang Q; Sun T; Liu W
Front Oncol; 2023; 13():1173275. PubMed ID: 37546405
[TBL] [Abstract][Full Text] [Related]
5. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
6. Correlative Study on the Relationship between the Expression of m6a-Related Genes and the Prognosis and Immunotherapy of Soft Tissue Sarcoma.
Qiu Y; Li J; Yao J; Meng J; Huang X; Zheng X; Wen Z; Huang J; Wang H
Biomed Res Int; 2022; 2022():5439023. PubMed ID: 38024481
[TBL] [Abstract][Full Text] [Related]
7. Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.
Bücklein V; Adunka T; Mendler AN; Issels R; Subklewe M; Schmollinger JC; Noessner E
Oncoimmunology; 2016 Jul; 5(7):e1178421. PubMed ID: 27622032
[TBL] [Abstract][Full Text] [Related]
8. Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis.
Perry LM; Cruz SM; Kleber KT; Judge SJ; Darrow MA; Jones LB; Basmaci UN; Joshi N; Settles ML; Durbin-Johnson BP; Gingrich AA; Monjazeb AM; Carr-Ascher J; Thorpe SW; Murphy WJ; Eisen JA; Canter RJ
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36599469
[TBL] [Abstract][Full Text] [Related]
9. Emerging Trends in Immunotherapy for Adult Sarcomas.
Husain M; Chen L; Liebner D; Beane J; Rubinstein M; Pollock R; Verschraegen C; Tinoco G
Oncologist; 2023 May; 28(5):e233-e241. PubMed ID: 36905579
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond.
Fazel M; Dufresne A; Vanacker H; Waissi W; Blay JY; Brahmi M
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980528
[TBL] [Abstract][Full Text] [Related]
12. Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy.
Sousa LM; Almeida JS; Fortes-Andrade T; Santos-Rosa M; Freitas-Tavares P; Casanova JM; Rodrigues-Santos P
Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359785
[TBL] [Abstract][Full Text] [Related]
13. Potential for immunotherapy in soft tissue sarcoma.
Tseng WW; Somaiah N; Engleman EG
Hum Vaccin Immunother; 2014; 10(11):3117-24. PubMed ID: 25625925
[TBL] [Abstract][Full Text] [Related]
14. Cancer Stem Cells in Soft-Tissue Sarcomas.
Martínez-Delgado P; Lacerenza S; Obrador-Hevia A; Lopez-Alvarez M; Mondaza-Hernandez JL; Blanco-Alcaina E; Sanchez-Bustos P; Hindi N; Moura DS; Martin-Broto J
Cells; 2020 Jun; 9(6):. PubMed ID: 32532153
[TBL] [Abstract][Full Text] [Related]
15. The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook.
Banks LB; D'Angelo SP
J Natl Compr Canc Netw; 2022 Jul; 20(7):834-844. PubMed ID: 35830892
[TBL] [Abstract][Full Text] [Related]
16. Prospects for NK Cell Therapy of Sarcoma.
Lachota M; Vincenti M; Winiarska M; Boye K; Zagożdżon R; Malmberg KJ
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322371
[TBL] [Abstract][Full Text] [Related]
17. Challenges of Using ICD-9-CM and ICD-10-CM Codes for Soft-Tissue Sarcoma in Databases for Health Services Research.
Hess LM; Zhu YE; Sugihara T; Fang Y; Collins N; Nicol S
Perspect Health Inf Manag; 2019; 16(Spring):1a. PubMed ID: 31019431
[TBL] [Abstract][Full Text] [Related]
18. The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy.
Crombé A; Roulleau-Dugage M; Italiano A
Cancer Commun (Lond); 2022 Dec; 42(12):1288-1313. PubMed ID: 36260064
[TBL] [Abstract][Full Text] [Related]
19. Adoptive immunotherapy against sarcomas.
Mesiano G; Leuci V; Giraudo L; Gammaitoni L; Carnevale Schianca F; Cangemi M; Rotolo R; Capellero S; Pignochino Y; Grignani G; Aglietta M; Sangiolo D
Expert Opin Biol Ther; 2015 Apr; 15(4):517-28. PubMed ID: 25516119
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor.
Baldi GG; Gronchi A; Tazzari M; Stacchiotti S
Expert Rev Anticancer Ther; 2022 May; 22(5):491-503. PubMed ID: 35412415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
